US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.89 ▼-1.02% TSLA $378.69 ▲+2.18% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.49 -0.01 (-0.06%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
36 37 Next >
News headline image
Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies ↗
The patient also had a recent CMV infection, which the company said could have contributed. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases ↗
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting. 
Via Benzinga
News headline image
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations ↗
A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
8 Analysts Have This To Say About Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
2 Growth Stocks to Buy Hand Over Fist in February ↗
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript ↗
SRPT earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was... 
Via StockStory
News headline image
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
News headline image
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in? 
Via MarketBeat
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years ↗
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development ↗
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones. 
Via Benzinga
News headline image
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst ↗
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway. 
Via Benzinga
News headline image
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well. 
Via Benzinga
News headline image
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
36 37 Next >